SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin surges on its arm getting USFDA approval for norethindrone tablets

21 Sep 2011 Evaluate

Lupin is currently trading at Rs 487.45, up by 4.85 points or 1.00% from its previous closing of Rs 482.60 on the BSE.

The scrip opened at Rs 486.65 and has touched a high and low of Rs 492.00 and Rs 484.30 respectively. So far 1,21,331 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 519.80 on 30-Nov-2010 and a 52 week low of Rs 363.00 on 25-Feb-2011.

Last one week high and low of the scrip stood at Rs 492.00 and Rs 469.50 respectively. The current market cap of the company is Rs 21547.94 crore.

The promoters holding in the company stood at 46.96% while Institutions and Non-Institutions held 42.76% and 10.28% respectively.

Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc. (LPI) has been granted final approval by the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to market a generic version of Watson’s NOR-QD tablets. The company will commence shipping its norethindrone tablets, USP 0.35 mg shortly.

NOR-QD (norethindrone tablets, USP 0.35 mg) is a progestin-only oral contraceptive indicated for the prevention of pregnancy. Combined annual sales for NOR-QD and its generic equivalents were approximately $52 million for the twelve months ended June 2011 based on IMS Health sales data.

Recently, Lupin Pharmaceutical Inc (LPI) had been granted final approval by the US Food and Drug Administration (FDA) for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of UCB’s Keppra XR tablets.

Lupin Share Price

2324.25 -2.25 (-0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×